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Abstract
 
Neutrophils are markedly less sensitive to glucocorticoids than T cells, making it difficult to
control inflammation in neutrophil-mediated diseases. Development of new antiinflammatory
strategies for such diseases would be aided by an understanding of mechanisms underlying dif-
ferential steroid responsiveness. Two protein isoforms of the human glucocorticoid receptor
(GR) exist, GR
 
a
 
 and GR
 
b
 
, which arise from alternative splicing of the GR pre-mRNA pri-
mary transcripts. GR
 
b
 
 does not bind glucocorticoids and is an inhibitor of GR
 
a
 
 activity. Rel-
ative amounts of these two GRs can therefore determine the level of glucocorticoid sensitivity.
In this study, human neutrophils and peripheral blood mononuclear cells (PBMCs) were stud-
ied to determine the relative amounts of each GR isoform.
The mean fluorescence intensity (MFI) using immunofluorescence analysis for GR
 
a
 
 was
475 
 
6
 
 62 and 985 
 
6
 
 107 for PBMCs and neutrophils, respectively. For GR
 
b
 
, the MFI was
350 
 
6
 
 60 and 1,389 
 
6
 
 143 for PBMCs and neutrophils, respectively (
 
P
 
 
 
,
 
 0.05). After interleu-
kin (IL)-8 stimulation of neutrophils, there was a statistically significant increase in intensity of
GR
 
b
 
 staining to 2,497 
 
6
 
 140 (
 
P 
 
,
 
 0.05). No change in GR
 
a
 
 expression was observed. This in-
version of the GR
 
a
 
/GR
 
b
 
 ratio in human neutrophils compared with PBMCs was confirmed by
quantitative Western analysis. Increased GR
 
b
 
 mRNA expression in neutrophils at baseline, and
after IL-8 exposure, was observed using RNA dot blot analysis. Increased levels of GR
 
a
 
/GR
 
b
 
heterodimers were found in neutrophils as compared with PBMCs using coimmunoprecipita-
tion/Western analysis. Transfection of mouse neutrophils, which do not contain GR
 
b
 
, resulted
in a significant reduction in the rate of cell death when treated with dexamethasone.
We conclude that high constitutive expression of GR
 
b
 
 by human neutrophils may provide a
mechanism by which these cells escape glucocorticoid-induced cell death. Moreover, upregu-
lation of this GR by proinflammatory cytokines such as IL-8 further enhances their survival in
the presence of glucocorticoids during inflammation.
 
Key words: neutrophils • glucocorticoid insensitivity • glucocorticoid receptor • interleukin 8 • 
inﬂammation
 
Introduction
 
Neutrophils have been implicated in the pathogenesis of
many diseases, including severe asthma (1, 2), psoriasis (3,
4), and a variety of collagen-vascular diseases (5, 6). These
cells are known to be less sensitive to glucocorticoids than
other white blood cell types (7). Moreover, glucocorticoid
treatment actually inhibits their cell death in vitro (8, 9).
This is in contrast to T cells, where workers have shown
that steroids induce apoptosis (10, 11). Thus, use of gluco-
corticoid therapy in the treatment of neutrophil-associated
inflammation is of major clinical concern in terms of dis-
ease resolution.
The mechanisms by which human T cell and neutrophil
apoptotic responses to glucocorticoids differ are unknown.
Glucocorticoid action is mediated through the glucocorti-
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coid receptor (GR),
 
1
 
 which is found in the cytosol of most
human cells (12). As the result of alternative splicing of the
GR pre-mRNA, there are two homologous mRNAs and
protein isoforms, termed GR
 
a
 
 and GR
 
b
 
. Both mRNAs
contain the same first eight exons of the GR gene (13–15).
The remainder is derived by alternative splicing of the last
exon of the GR gene, resulting in either inclusion or ex-
clusion of exon 9
 
a
 
. The two protein isoforms have the
same first 727 NH
 
2
 
-terminal amino acids. GR
 
b
 
 differs
from GR
 
a
 
 only in its COOH terminus with replacement
of the last 50 amino acids of GR
 
a
 
 with a unique 15 amino
acid sequence lacking a steroid binding domain. These dif-
ferences render GR
 
b
 
 unable to bind glucocorticoids, re-
duces its binding affinity for DNA recognition sites, abol-
ishes its ability to transactivate glucocorticoid-sensitive
genes, and makes it function as a dominant inhibitor of
GR
 
a
 
, possibly through formation of antagonistic GR
 
a
 
/
GR
 
b
 
 heterodimers (13, 16–18).
In this study, we confirm that T cells and neutrophils re-
spond differentially to dexamethasone (DEX), the model
steroid used. We have also found that IL-8 synergizes with
DEX to decrease neutrophil cell death in vitro, and that
both of these responses are associated with increases in the
ratio of GR
 
b
 
 to GR
 
a
 
. These observations suggest an alter-
nate mode of action of GRs in neutrophils than that ob-
served in PBMCs. On the one hand, glucocorticoids are
ineffective at resolving neutrophil-associated inflammation.
On the other hand, as glucocorticoids reduce the spontane-
ous cell death of these cells, neutrophils must be glucocor-
ticoid-sensitive but simply do not react in the same manner
as T cells. Therefore, in this study, two different ap-
proaches were chosen in an attempt to determine whether
shifts in GR
 
b
 
 to GR
 
a
 
 levels could account for these differ-
ent responses to steroids. First, by quantitating the relative
levels of GR
 
a
 
 and GR
 
b
 
 in human neutrophils, in terms of
protein and mRNA levels. Then second, because mouse
neutrophils have no GR
 
b
 
, assessing whether introduction
of the GR
 
b
 
 gene into mouse neutrophils changes the ef-
fects of glucocorticoids on neutrophil cell death.
 
Materials and Methods
 
Preparation of PBMCs.
 
Heparinized venous blood from nor-
mal healthy volunteers was layered on a Ficoll-Paque density gra-
dient (Amersham Pharmacia Biotech) and centrifuged for 25 min
at 400 
 
g
 
 at room temperature. The PBMC layer was aspirated,
washed, and resuspended in HBSS (GIBCO BRL), then counted.
PBMCs were always 
 
.
 
95% viable, as determined by a trypan
blue (Sigma-Aldrich) exclusion assay.
 
Preparation of Human Neutrophils.
 
Human neutrophils were
isolated from normal healthy individuals using a Percoll (Amer-
sham Pharmacia Biotech) density gradient (19). In brief, 4.4 ml of
3.8% (wt/vol) sodium citrate (Fisher Scientific) was added to 40
ml of heparinized venous blood. The blood was then centrifuged
at 400 
 
g
 
 for 20 min. The plasma layer was then removed, 5 ml of
6% (wt/vol) dextran (Amersham Pharmacia Biotech) was then
added to the pelleted whole blood, and the total volume was
brought up to 50 ml with saline and mixed gently. The cell sus-
pension was then left for 30 min at room temperature to allow
the red blood cells to settle. The upper white blood cell layer was
removed, centrifuged at 400 
 
g
 
 for 10 min, the supernatant dis-
carded, and the pellet resuspended in 2 ml of autologous plasma.
The cell suspension was then underlaid first with a 42% (wt/vol),
then a 51% (wt/vol) Percoll gradient and centrifuged at 350 
 
g
 
 for
10 min. The resulting neutrophil rich layer was carefully re-
moved. Neutrophils were then resuspended in PBS, centrifuged
at 350 
 
g
 
 for 10 min, and the supernatant discarded. The resulting
neutrophil pellet was then resuspended in HBSS.
 
Preparation of Murine Neutrophils.
 
For preparation of murine
neutrophils, individual BALB/c female mice were given a 1 ml
intraperitoneal injection of 4% (wt/vol) Brewer’s thioglycollate
(DIFCO). After 4 h, the mice were killed by cervical dislocation
and the peritoneal cavity washed with cold 1
 
3
 
 PBS, 5 mM
EDTA (Sigma-Aldrich). The PBS/EDTA cell suspension was
harvested with a syringe, pelleted by centrifugation, and resus-
pended in 3 ml 1
 
3
 
 HBSS. The resulting cell suspension was then
layered over a 55/65/81% Percoll gradient and centrifuged at
3,000 rpm for 20 min. Neutrophils were harvested at the 65/81%
interface. Harvested neutrophils were then washed in 1
 
3
 
 HBSS,
resuspended in RPMI, 10% FCS, and counted.
 
Preparation of PBMC and Neutrophil Cytospins.
 
Cells were re-
suspended at 0.5 
 
3
 
 10
 
6
 
 cells/ml in HBSS. 50 
 
m
 
l of each cell sus-
pension was cytospun onto individual microscope slides for 3 min
at 300 rpm, air dried, then fixed for 10 min in 4% (wt/vol)
paraformaldehyde (Sigma-Aldrich), and washed in PBS. The
cytospins were then washed in PBS, air dried, and stored at
 
2
 
80
 
8
 
C until use.
 
Immunofluorescence Staining of Neutrophils and PBMCs for GR
 
a
 
and GR
 
b
 
.
 
Cytospins of both cell types were incubated for 15
min at room temperature with permeabilizing solution (PBS con-
taining 0.5% [wt/vol] BSA, 0.1% [vol/vol] Tween 20, and 0.1%
[wt/vol] saponin [Sigma-Aldrich]). The permeabilizing solution
was then tipped off and the cytospins were blocked with a com-
mercial blocking solution (Superblock; Scytek) for 15 min at
room temperature. After the incubation period, the blocking so-
lution was aspirated off and discarded. Cytospins were then incu-
bated with affinity-purified polyclonal antibodies to human GR
 
a
 
(Affinity BioReagents, Inc.) or anti-GR
 
b
 
 (preparation and speci-
ficity as described in references 13, 20, and 21) and diluted in per-
meabilizing solution. Purified nonimmune rabbit IgG (Southern
Biotechnology Associates, Inc.) served as the control. The
cytospins were then incubated overnight at 4
 
8
 
C. After the incu-
bation period, the cytospins were washed in PBS, 0.1% Tween
20 for 15 min at room temperature with gentle agitation, then
incubated with a goat anti–rabbit F(ab
 
9
 
)
 
2 
 
FITC conjugate (Dako)
for 30 min at room temperature and washed in PBS, 0.1%
Tween 20 for 15 min at room temperature with gentle agitation.
Cytospins were then mounted and examined by fluorescence mi-
croscopy. Intensity of GR staining was assessed using image anal-
ysis software (IPLab Spectrum; Signal Analytics Corporation) and
expressed as mean fluorescence intensity (MFI).
 
Quantitative Western Analysis.
 
Quantitative Western analysis
was performed using specific anti-GR
 
a
 
 and GR
 
b
 
 polyclonal an-
tibodies produced in our laboratory as described previously (13).
The GR
 
a
 
-directed antibody has been extensively employed in
detailed analyses of GR
 
a
 
 proteolytic cleavage (20). PBMCs and
 
1
 
Abbreviations used in this paper: 
 
DEX, dexamethasone; GR, glucocorticoid
receptor; MFI, mean fluorescence intensity; pGFP, plasmid green fluores-
cent protein; PI, propidium iodide; pRSh, plasmid Rous sarcoma (hu-
man); TUNEL, terminal deoxynucleotidyl transferase–mediated dUTP-
biotin nick end-labeling. 
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neutrophils were lysed at 4
 
8
 
C, and 100 
 
m
 
g protein was applied to
a 8% precast polyacrylamide-SDS gels (Novex) and electropho-
resed in parallel with prestained markers (SeeBlue™; Novex) to
estimate molecular weight; increasing concentrations of peptide-
BSA conjugate standard (5–25 ng corresponding to 70–360 fmol)
were also used for quantitation. Proteins were transferred to ni-
trocellulose membranes and blocked in 5% nonfat milk for 1 h.
Immunoblotting was performed at 4
 
8
 
C overnight using purified
GR
 
a
 
- and GR
 
b
 
-specific polyclonal antibodies at 10 
 
m
 
g/ml. The
specificity of these antibodies were described in references 13, 20,
and 21. After washing, the blots were incubated at room temper-
ature with peroxidase-conjugated anti–rabbit immunoglobulin
antibody (Dako) at 1:4,000 dilution. Blots were washed and ex-
posed to chemiluminescence solution for 1 min. (ECL kit; Amer-
sham Pharmacia Biotech), followed by exposure to X-OMAT
AR films (Eastman Kodak Co.). Band densities of the standards
and the samples developed on the film were scanned and saved
on computer disks for densitometry using the NIH image system
1.61 program.
 
Demonstration of GR
 
a
 
/GR
 
b
 
 Heterodimers by Western Blot Analy-
sis.
 
3 
 
3 
 
10
 
6
 
 PBMCs or neutrophils were lysed in a buffer con-
taining the following protease inhibitors: 0.5 M EDTA, 0.5 mM
PMSF, and 10 
 
m
 
g/ml of leupeptin, aprotonin, antipain, and pep-
statin (Sigma-Aldrich). The cell lysates were left on ice for 10 min
and then centrifuged for 10 min at 13,000 rpm. The supernatant
was removed and then incubated overnight at 4
 
8
 
C with sepharose
beads (Amersham Pharmacia Biotech) covalently linked to a
polyclonal antibody that recognized GR
 
a
 
. The beads were then
centrifuged at 13,000 rpm for 30 s. The pelleted beads were then
resuspended in loading buffer (0.125 M Tris-HCl [Sigma-
Aldrich], 4% [wt/vol] SDS, and 10% [vol/vol] 
 
b
 
-mercaptoetha-
nol [Boehringer]).
The beads were then boiled for 5 min and loaded onto a 10%
Tris-HCl polyacrylamide mini-gel (Bio-Rad Laboratories) under
reducing conditions. The gel was run at 80 V in a running buffer
containing the following: 0.3% (wt/vol) Tris-HCl, 1.4% (wt/vol)
glycine, and 0.1% (wt/vol) SDS (Boehringer), until the loading
dye reached the end of the gel. After the electrophoresis, the pro-
tein was transferred to nitrocellulose paper (Bio-Rad Laborato-
ries) at 50 mA for 1 h using a semidry transfer system (BioRad
Laboratories). The transfer buffer contained the following: 48
mM Tris-HCl (Sigma-Aldrich), 39 mM glycine, and 20% metha-
nol (Sigma-Aldrich). The nitrocellulose paper was then blocked
overnight at 4
 
8
 
C with 5% BSA (wt/vol; Sigma-Aldrich) in 1
 
3
 
dilution buffer (0.2 M Tris-HCl, 0.2% Tween 20, 25 mM Tris-
HCl, pH 6.8; Sigma-Aldrich). After the incubation period, the
membrane was incubated for 2 h at room temperature with an
antibody specific to GR
 
b
 
. The antibody was diluted in PBS con-
taining 0.1% (vol/vol) Tween 20 (Sigma-Aldrich) and 1% (wt/
vol) BSA (Sigma-Aldrich). After the incubation period, the
membrane was washed in PBS, 0.1% (vol/vol) Tween 20 for 1 h,
then incubated for 1 h with an anti–rabbit horseradish peroxidase
conjugate (Dako) diluted in 1% BSA (Sigma-Aldrich) in 1
 
3
 
 dilu-
tion buffer. The membrane was then washed in 1% BSA (Sigma-
Aldrich) 1
 
3
 
 dilution buffer for 1 h at room temperature, and spe-
cific bands were visualized using a commercial chemilumines-
cence detection system (ECL; Amersham Pharmacia Biotech).
 
RNA Dot Blot Analysis.
 
Total cytoplasmic RNA was isolated
from 10
 
7
 
 cells (PBMCs or neutrophils) as follows: the cells were
cracked in buffer (20 mM Tris-HCl, pH 7.8, 10% glycerol, 50
mM NaCl, 3 mM MgCl2, and 0.5 mM EDTA) containing 0.5%
NP-40 and 10 mM vanadyl ribonucleoside complex. Nuclei
were removed by centrifugation at 1,000 g. RNA was subjected
to phenol/chloroform extraction and EtOH precipitation. The
RNA was applied to nitrocellulose sheets using vacuum transfer
(Bio-Rad Laboratories), and cross-linked at 808C under vacuum
for 2 h. GR RNA was detected by hybridization to 50 base,
biotinylated probes. Total GR (GRa plus GRb) was detected
with a probe to exon 9-b: 59-TTTTAGTCTAATTACACA-
CTCTACACGAAAGACCAAAATTGGTGTATTG-39. GRa
RNA was detected with an oligonucleotide that specifically rec-
ognized exon 9-a: 59-TACCAGAATAGGTTTTTACAAAC-
CTTCGTTATCAATTCCTCTAAAAGTTG-39.
It was not possible to probe for GRb mRNA specifically in
these studies due to poor specificity of the oligonucleotide probe
directed to the exon 8/9b junction, which is the only part of the
GRb mRNA which is not also included in the GRa mRNA.
Specificity of the probes was verified by hybridization to GRa
and b cDNAs prepared from the expression plasmids Rous sar-
coma human (pRSh) GRa and pRSh GRb. Cross-hybridization
of the biotinylated GRa probe to cDNA derived from pRSh
GRb was not noted. After hybridization, the blots were incu-
bated in buffer with streptavidin-linked alkaline phosphatase
(Bio-Rad Laboratories), and specific bands were visualized using
a chromogenic system comprising 4-nitro blue tetrazolium chlo-
ride and 5-bromo-4-chloro-3-indolyl phosphate (Boehringer).
Transfection of murine neutrophils with a GRb containing
plasmid neutrophils were transfected with pRSh GRb that con-
tains the full-length coding region of GRb under the control of
the constitutively active Rous sarcoma virus promoter (18). As a
control, a commercially available plasmid vector was used, plas-
mid green fluorescent protein (pGFP)-C1 (CLONTECH Labo-
ratories, Inc.). Reversible permeabilization of cells using the
pore-forming agent, streptolysin O, was used to enhance uptake
of the plasmid (22, 23). Streptolysin O (Lee Laboratories) was
preactivated with 5 mM dithiothreitol (DTT; Bio-Rad Laborato-
ries) for 2 h at room temperature, then added to a transfection
medium (TM) consisting of RPMI 1640, 40 mM l-glutamine,
and 20 mM Hepes (GIBCO BRL) at a concentration of 20 U/ml
with 10 mg of plasmid (pRSh GRb or pGFP-C; CLONTECH
Laboratories, Inc.). Freshly isolated murine neutrophils (described
above) were then resuspended (4 3 106 cells total) in 200 ml of
this streptolysin O/TM/plasmid medium and incubated for 5
min at 378C. The cells were then resuspended at 106/ml in of
RPMI 1640, 40 mM l-glutamine, 20 mM Hepes, and 10% (vol/
vol) FCS (GIBCO BRL). Confirmation of GRb expression of
pRSh GRb transfected cells was confirmed by immunofluores-
cence (IMF) staining. The method used is described in full ear-
lier; however, the secondary antibody used for this staining was
an anti–rabbit Cy3 conjugate (Jackson ImmunoResearch Labora-
tories). Transfection efficiency was determined by capturing im-
ages of 10 fields per sample, and counting the number of GFP-
positive cells. Identification of negative cells was accomplished by
nuclear counterstaining with 300 nM 49,6-diamidino-2-phe-
nylindole (DAPI; Sigma-Aldrich). Transfection efficiency was
calculated as the average percentage of GFP-positive cells per
field.
Evaluation of DEX Effect on pRSh GRb-transfected Murine Neu-
trophil Cell Death. Cells were cultured overnight in 48-well flat-
bottomed plates with or without 1026 M DEX (Sigma-Aldrich).
After this incubation period, cells were washed and resuspended
in 600 ml of 13 PBS. Each individual sample (n = 7) was divided
in two 300-ml aliquots one of which received no treatment as a
control the other was stained with propidium iodide (PI; Sigma-
Aldrich) at a final concentration of 0.3 mg/ml. PI positivity was
determined by flow cytometry (FACScan™; Becton Dickinson)588 Increased Glucocorticoid Receptor b in Neutrophils
and expressed as percentage of positive cells. Cells were also ana-
lyzed via terminal deoxynucleotidyl transferase-mediated dUTP-
biotin nick end-labeling (TUNEL) to confirm that PI staining
corresponded well with TUNEL staining.
Statistical Methods. Immunofluorescence and the cell death/
transfection data were analyzed using the Student’s t test.
Results
GR Protein and mRNA Levels in Human Neutrophils.
Freshly isolated PBMCs and neutrophils expressed both
GR isoforms. By immunofluorescence, the GRs were lo-
calized to the cytoplasm of both cell types (Fig. 1), al-
though in some cases a subpopulation of neutrophils did
exhibit strong baseline nuclear staining (data not shown). In
neutrophils, GRb immunoreactive protein was expressed
at a higher level than GRa (Fig. 1, B and A, respectively).
Of interest, when neutrophils were incubated with IL-8, a
marked upregulation of GRb immunoreactivity was ob-
served (Fig. 1 C). Conversely in PBMCs, GRa protein
was expressed at a higher level than GRb (Fig. 1, D and E,
respectively).
Using image analysis, we were able to quantify the rela-
tive intensity of GRb and GRa staining by MFI (Fig. 2)
and confirm our observation of the high expression of
GRb in neutrophils. For PBMCs and neutrophils, the
GRa MFIs were 475 6 62 and 985 6 107, respectively. In
contrast, GRb MFIs were 350 6 60 vs. 1,389 6 143 (P ,
0.05) in PBMCs versus neutrophils, respectively. After IL-8
stimulation of neutrophils for 24 h, there was a significant
further increase in the intensity of GRb staining to 2,497 6
140 (P , 0.05 compared with medium control). However,
no change in GRa expression was observed.
To quantify the absolute amounts of GRa and GRb
contained in the cells, we performed quantitative Western
analysis of cell extracts. Immunoreactive GRa and GRb
(Fig. 3), expressed as fmol/mg protein, showed higher con-
centrations of GRa than GRb in PBMCs (GRa: 12.0 6
2.1; GRb: 0.78 6 0.2; mean 6 SEM). In contrast, GRb
was expressed at higher concentrations than GRa in neu-
trophils (GRa: 1.6 6 1.0; GRb: 4.2 6 0.9; mean 6
SEM). Thus, in keeping with the IMF data, GRb was ex-
pressed at higher level in neutrophils than PBMCs. The
relative GRb/GRa ratio (calculated as mean GRb/GRa
ratio of individual samples) was 73-fold higher in neutro-
phils (4.4 6 1.6; mean 6 SEM) than PBMCs (0.06 6
0.007; mean 6 SEM). When the two populations of cells
were compared, a significant difference was found analyz-
ing the GRa expression (neutrophils versus PBMCs; P 5
0.003; t test), as well as the GRb expression (neutrophils
versus PBMCs; P 5 0.03; Mann-Whitney Rank Sum test),
and the GRb/GRa ratio (neutrophils versus PBMCs; P 5
0.03; Mann-Whitney Rank Sum test).
RNA Dot Blot Analysis. Dot blot analysis of mRNA
levels revealed that GRa mRNA in PBMCs was expressed
at a higher level than GRb mRNA (Fig. 4, lane 1). How-
ever, in neutrophils, GRb mRNA was expressed at a
greater level than GRa mRNA (Fig. 4, lane 2). After over-
night stimulation of neutrophils with IL-8, there was an in-
Figure 1. Immunofluorescence
staining of PBMCs and neutro-
phils was performed using anti-
bodies specific for either GRa or
GRb. A and B show GRa and
GRb expression in resting neu-
trophils, respectively. After IL-8
stimulation, GRb expression was
increased as shown in C. In com-
parison, PBMCs were also stained
for GRa and GRb, which are
shown in D and E, respectively.
However, these GRs are ex-
pressed at a lower level than in
neutrophils. F is a negative con-
trol consisting of affinity-purified
rabbit IgG for the neutrophil
staining (360 objective).589 Strickland et al.
crease in total GR and GRb mRNA levels. However, IL-8
reduced GRa mRNA to undetectable levels (Fig. 4, lane
3). Thus, the IL-8–induced increase in total GR in neutro-
phils can be attributed to increased GRb.
Presence of GRa/GRb Heterodimers in Neutrophils. High
levels of GRb may contribute to the formation of GRa/
GRb heterodimers in neutrophils which could antagonize
the function of GRa/GRa homodimers (13, 17, 19).
Therefore, we sought to determine the presence of het-
erodimers in neutrophils. An anti-GRa antibody was used
to immunoprecipitate both GRa and complexes contain-
ing GRa. The immunoprecipitate was electrophoresed on
an agarose gel and then immunoblotted with an antibody
specific for GRb to detect GRa/GRb heterodimers.
Neutrophils (Fig. 5, lanes 5–8) were found to contain
markedly higher levels of GRa/GRb heterodimers than
found in PBMCs (Fig. 5, lane 1–4). Beads alone did not
precipitate any GRa or GRb (data not shown). These data
demonstrate that GRa/GRb heterodimers are present in
freshly isolated neutrophils at higher levels than found in
PBMCs.
Effect of Dexamethasone and IL-8 on Neutrophil Cell Death.
Given the observation of heterodimer formation between
GRa and GRb in human neutrophils, which could result
in antagonism of GR activity, we examined neutrophils for
their apoptotic responses to DEX in the presence and ab-
sence of IL-8. This analysis was performed using PI to stain
dead cells in the population, which correlated well with
TUNEL analysis, indicating that the cells had died via ap-
optosis. No significant reduction in the percentage of PI-
positive cells was observed by incubation with IL-8 alone
compared with the control (Fig. 6). However, incubation
with DEX caused a significant decrease in PI-positive cells
Figure 2. Expression of GRa and GRb protein in PBMCs and neu-
trophils. The staining of the two cell types was quantified and expressed as
MFI using image analysis software. GRb expression was significantly
higher in neutrophils than PBMCs (P , 0.05). There was also a statisti-
cally significant increase in GRb expression in neutrophils after IL-8 ex-
pression (P , 0.05). The mean 6 SEM from four separate donors are
shown.
Figure 3. Quantitative Western blot analysis for GR in PBMCs and
neutrophils. GRb levels are shown to be much higher than GRa in hu-
man neutrophils. In contrast, GRa was found to be the predominant GR
in PBMCs. Absolute GR quantities are expressed in fmol/mg of cellular
protein and stated above each lane.
Figure 4. RNA dot blot anal-
ysis for GR mRNA in PBMCs
and neutrophils. (A) RNA dot
blot probed for the presence of
exon 9a, which is only present
in mRNA encoding GRa. Lane
1, cytoplasmic RNA from hu-
man PBMC; lane 2, cytoplasmic
RNA from human neutrophils;
and lane 3, cytoplasmic RNA
from human neutrophils prein-
cubated with IL-8. (B) RNA dot
blot probed for the presence of
exon 9b, which is present in
mRNA encoding both GRa
and GRb. Lane 1, cytoplasmic
RNA from human PBMCs; lane
2, cytoplasmic RNA from hu-
man neutrophils; and lane 3, cy-
toplasmic RNA from human
neutrophils preincubated with
IL-8. Relative density of the
spots is represented graphically
above each blot. These blots are
representative of three experi-
ments on three separate donors.
Figure 5. GRa/GRb heterodimers are present in neutrophils. The
GRa protein in neutrophils and PBMCs were immunoprecipitated with
a GRa-specific antibody, then Western blotted with an anti-GRb–spe-
cific antibody. PBMCs showed weak bands indicating low levels of het-
erodimers (lanes 1–4). In contrast, neutrophils demonstrated strong GRb
staining, indicating a high level of GRa/GRb heterodimers (lanes 5–8).590 Increased Glucocorticoid Receptor b in Neutrophils
compared with the control (P , 0.05). This rescue from
cell death was further increased by incubation with IL-8
and DEX together (P , 0.01; Fig. 6).
Transfection of Murine Neutrophils with pRSh GRb Expres-
sion Vector Alters Their Response to DEX. The association
between elevated GRb and reduced apoptosis in response
to DEX raised the question of whether GRb directly en-
ables neutrophils to reduce their rate of apoptosis in re-
sponse to DEX. As it is known that mice do not express
GRb, they make an ideal model in which to temporarily
cause expression of GRb to answer this question (24).
Transient expression of human GRb in primary murine
neutrophils required development of a method to effi-
ciently introduce plasmid DNA into the cells. To accom-
plish this, we relied on transient permeabilization of the
cells with streptolysin O, which has been employed in a
similar manner by others (22, 23). Permeabilization of the
neutrophils in the presence of plasmid DNA encoding GFP
under control of the CMV immediate early promoter re-
sulted in efficient uptake and expression of the plasmid (Fig.
7). Plasmid transfection efficiency was 63 6 10% (mean 6
SEM) as assessed by measuring the percentage of cells ex-
pressing GFP (Fig. 7 B). Cells that had been treated with
streptolysin O in the presence of a control plasmid, which
did not encode GFP, showed no fluorescence (Fig. 7 D).
In contrast to the antiapoptotic effect of DEX on human
neutrophils, treatment of mouse neutrophils with DEX in-
creased their rate of cell death as measured by PI uptake
(see Fig. 8; control pGFP). Unstained cells from each test
sample served as a negative control to allow appropriate
gating. To examine whether this effect could be due to the
lack of GRb expression in these cells, freshly isolated neu-
trophils from BALB/c mice were transfected with pRSh
GRb. In these experiments (n 5 7), successful transfection
was confirmed by demonstrating murine neutrophils to
stain positive with anti-GRb antibody after pRSh GRb
(Fig. 7 F), but not control (Fig. 7 E), plasmid transfection.
This difference between the two plasmid treatments was
found to be highly significant (P , 0.001) as determined by
a paired Student’s t test.
As shown in Fig. 8, treatment of the transfected neutro-
phils with DEX caused the cells treated with control plas-
mid pGFP to increase their rate of cell death by 9.4 6
3.2%, similar to untreated murine neutrophils. However,
cells transfected with pRSh GRb decreased their rate of
cell death in response to DEX by 13.7 6 3.5%.
Discussion
The mechanism by which neutrophils respond differ-
ently than T cells to glucocorticoids has not been resolved,
although it is generally agreed that the GR must be inti-
mately involved. Kato et al. (25) demonstrated that treat-
ment of neutrophils with DEX significantly inhibited both
spontaneous and TNF-a–induced cell death. Moreover,
this effect was completely reversed by a GR antagonist,
RU 38486, and by cycloheximide. Similarly, Liles et al. (8)
demonstrated that glucocorticoid treatment of neutrophils
could inhibit cell death by up to 90%. GRb attenuates
GRE-mediated pathways (14) and may therefore provide a
natural mechanism for reducing glucocorticoid-induced
cell death. The results of our studies confirm that DEX
causes a reduction in the rate of spontaneous cell death by
neutrophils. In addition, we have made a novel observation
that preincubation of neutrophils with IL-8 dramatically
enhances the protective effect of DEX.
These studies also illustrate that the ratio of GRb to
GRa is 73-fold greater in neutrophils than in PBMCs (Fig.
3). This reflects differences observed in relative abundance
of the mRNAs (Fig. 4). If an activity of GRb is to attenu-
ate GR binding and activation of GRE in response to
DEX, we would expect to find GRa/GRb heterodimers
in neutrophils after incubation with DEX, which were in-
deed much more abundant in neutrophils than in PBMCs
(Fig. 5). Heterodimers have only 15–20% of the transacti-
vating activity of GRa homodimers (13). The rate of cell
death in T lymphocytes is thought to be mediated through
GRa homodimers acting on GREs of glucocorticoid-sen-
sitive genes (26). If the same mechanism is active in neutro-
phils, then the net effect of promoter activation via GRa
homodimers binding to GRE should be to promote cell
death. However, DEX acts contrary to expectations in hu-
man neutrophils by promoting cell survival. In our studies,
the prosurvival activity of DEX is associated with elevated
GRb in freshly isolated neutrophils, perhaps through for-
Figure 6. The effect of IL-8 and/or DEX on human neutrophil spon-
taneous cell death. No significant reduction in the percentage of PI-posi-
tive cells was observed by incubation with IL-8 alone. However, incuba-
tion with DEX showed a significant decrease in PI-positive cells
compared with the control. Moreover, this rescue from cell death was
further increased by incubation with IL-8 and DEX together.591 Strickland et al.
mation of GRa/GRb heterodimers (Fig. 5). When the
GRb to GRa ratio is increased after incubation with IL-8,
the prosurvival effect of DEX is increased (Fig. 6).
Although the prosurvival effect of DEX on human neu-
trophils is associated with elevated levels of GRb, addi-
tional evidence is required to assert that GRb is function-
ally responsible for this effect. To properly confirm that
GRb is responsible for the prosurvival effects of DEX on
neutrophils, it is useful to examine the effect of DEX on
neutrophils which completely lack GRb. As it is known
that mouse cells do not express the GRb isoform of the
GR (24), the mouse makes an ideal model for studying the
role of GRb in neutrophils in response to glucocorticoids.
It is known that endogenous steroids such as cortisol can
differ in both magnitude and mechanism of action; how-
ever, in this study DEX was chosen as the model steroid.
Our data indicate that in contrast to human neutrophils,
mouse neutrophils increase their rate of cell death in re-
sponse to DEX (Fig. 8). This indicates that in the absence
of GRb, mouse neutrophils respond to DEX in the same
manner as human PBMCs. However, there may be other
important differences between human and murine neutro-
Figure 7. Transfection of
mouse neutrophils with either
pGFP or pRSh GRb induces
human GRb protein expres-
sion. A (bright field) and B (fluo-
rescence) show mouse neutro-
phils transfected with pGFP.
Positive cells (green fluores-
cence) are observed in B. Nega-
tive cells (blue fluorescence) was
visualized by counterstaining
with DAPI (see Materials and
Methods). Transfection effi-
ciency was 63% in the experi-
ment shown. Transfection effi-
ciency was measured in two
additional experiments, and
found to vary from 63 to 70%. C
(bright field) and D (fluores-
cence) show mouse neutrophils
transfected with pCLeco as a
control. Negative cells are ob-
served in D (340 objective). E
are pRSh GRb mouse neutro-
phils stained with a negative
control antibody (rabbit IgG).
Weak background staining is ob-
served. F shows pRSh GRb
transfected neutrophils with
many GRb positively stained
cells (360 objective).592 Increased Glucocorticoid Receptor b in Neutrophils
phils, and therefore proof of a functional role for GRb in
neutrophils requires that inducing GRb expression in
mouse neutrophils causes the effect of DEX to switch from
promotion of cell death to promotion of cell survival.
To induce GRb expression in murine neutrophils, we
had to develop a method to efficiently transfect this cell
type, which has not previously been reported. After exten-
sive screening of lipid-based transfection reagents and con-
ditions for electroporation, we succeeded in transfecting
primary murine neutrophils using streptolysin O to tran-
siently permeabilize the cells in the presence of an pGFP
expression vector driven by the CMV immediate early
promoter. As shown in Fig. 7 B, this technique resulted in
z63% of the cells expressing GFP, 18 h after transfection.
Inducing GRb expression in mouse neutrophils via
transfection of pRSh GRb was also successful, as shown in
Fig. 7 F. In fact, the observed transfection efficiency may
have been somewhat higher due to the greater fluorescence
quantum yield of the Cy3-conjugated secondary antibody
used to detect GRb relative to GFP. Induction of human
GRb expression in murine neutrophils did indeed alter the
effect of DEX on them from promoting cell death, as in
human PBMCs, to promoting cell survival, as in human
neutrophils. Therefore, induction of GRb expression in
mouse neutrophils resulted in a steroid insensitivity pattern
similar to that of human neutrophils.
Whether GRb has a functional role in steroid resistance
has been a matter of major controversy. Bamberger et al.
(14) and Oakley et al. (17, 18) have both found that trans-
fecting increasing amounts of GRb expression vectors into
various cell types inhibits the transactivating ability of Gra.
The main argument against this isoform having a functional
role is its lack of a steroid binding domain. De Lange et al.
(27) showed that even in the presence of 10-fold excess of
GRb, GRa was still able to activate transcription from the
mouse mammary tumor virus (MMTV) promoter at the
same rate. Similarly, Hecht et al. (28) were unable to dem-
onstrate an inhibitory role for GRb when transfected into
COS7 cells. These discrepant results may be explained by
the use of different vector systems, differences in cell or tis-
sue specificity, or insufficient GRb expression due to the
transient transfection method used. Work presented in our
study further delineates the mode of GRb action and dem-
onstrates a physiological role for this receptor in neutrophils.
The data presented in this study demonstrate for the first
time a role for GR in neutrophils. This observation implies
an interaction between this receptor and DEX despite the
absence of a glucocorticoid binding domain. One possible
explanation of this would be through GRb complexing
with GRa/DEX and exerting a cellular effect via forma-
tion of a heterodimer which is distinct from that of the ho-
modimer rather than simply attenuating transcription from
GREs. Moreover, as GRb was found to be the predomi-
nant GR isoform in neutrophils, it follows that het-
erodimer, rather than homodimer, formation would be fa-
vored in these cells. Oakley et al. (17) demonstrated that
use of a truncated form of GRb (hGR728T) which lacked
the unique 15 amino acids at the COOH terminus does
not repress the transcriptional activity of GRa. This final
portion of the GRb is also important in the heterodimer-
ization with GRa. The authors hypothesized that het-
erodimer formation may reduce the transcriptional activity
of GRa by denying access to GREs. An alternative expla-
nation may be that different glucocorticoid-induced signal-
ing pathways (one inducing apoptosis that can be inhibited
by GRb, and one reducing apoptosis that can not be inhib-
ited by GRb) may be used in cells expressing high levels of
GRb. The first pathway may be GRE dependent and the
latter dependent on interaction of GR with other tran-
scription factors like activating protein 1 (AP-1) or nuclear
factor (NF)-kB, as the latter mechanism can not be inhib-
ited by GRb (29).
In conclusion, the elevated GRb to GRa ratio in freshly
isolated neutrophils provides a novel mechanism by which
neutrophils escape glucocorticoid-induced cell death in
vivo. Moreover, the inflammatory environment in itself
may increase neutrophil insensitivity by increasing the ratio
of GRb to GRa, promoting further heterodimer forma-
tion. These data suggest that strategies aimed at reducing
expression of GRb in neutrophils may provide a starting
point for the development of novel antiinflammatory treat-
ments for neutrophil-associated disease.
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Figure 8. Effect of pRSh GRb vs. pGFP transfection on DEX-
induced cell death by mouse neutrophils as measured by PI uptake. This
shows the change in neutrophil PI positivity after DEX treatment in neu-
trophils transfected with either pRSh GRb or control pGFP. Neutrophils
transfected with pRSh GRb showed a decrease in PI positivity as op-
posed to the control pGFP-treated neutrophils where an increase in PI
positivity was observed.593 Strickland et al.
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